{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:46:15Z","timestamp":1791053175075,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":2137,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:p>Currently, 14 intact, unconjugated, monoclonal antibodies (Mabs) are approved for therapeutic use in the United States, and more than 100 Mabs are presently undergoing clinical development or regulatory review. Mabs are large molecular weight glycoproteins that embody structural, biochemical, and pharmacologic properties distinct from other biologics or chemically synthesized compounds. Early therapeutic Mabs were murine proteins, and clinical testing of these agents revealed serious immune\u2010mediated toxicities. The side effect profile of murine Mab therapeutic agents restricted the clinical development of these agents to indications with high morbidity and\/or mortality (ie, oncology, graft vs host rejection). Advances in genetic engineering and protein expression technologies resulted in the development of Mabs composed either predominately (ie, mouse\/human chimeric, \u201chumanized\u201d) or completely (ie, \u201cfully human\u201d Mabs) of the human amino acid sequence. The production of chimeric, humanized, and fully human Mabs significantly reduced the immune\u2010mediated toxicities and expanded the utility for these agents in numerous therapeutic areas, particularly in chronic disorders requiring either long\u2010term administration (ie, rheumatoid arthritis) or treatment upon the flare up of disease (Crohn's disease, psoriasis). This review provides an overview of the molecular, biochemical, and pharmacokinetic properties and clinical development history of Mabs and details how these factors currently affect the scope and design of early clinical development strategies for these drug candidates. Emphasis is placed on the criteria for selecting appropriate subject populations for phase I testing of Mabs.<\/jats:p>","DOI":"10.1177\/0091270006298360","type":"journal-article","created":{"date-parts":[[2007,4,18]],"date-time":"2007-04-18T05:28:11Z","timestamp":1176874091000},"page":"553-565","source":"Crossref","is-referenced-by-count":87,"title":["Molecular, Biologic, and Pharmacokinetic Properties of Monoclonal Antibodies: Impact of These Parameters on Early Clinical Development"],"prefix":"10.1002","volume":"47","author":[{"given":"Mary Ann","family":"Mascelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Getsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"Abernethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"Section 351 of the Public Health Service Act.Food and Drug Administration\u2014Center for Drug Evaluation and Research."},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2004.09.007"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(03)00008-6"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.7.4265"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10347"},{"key":"e_1_2_7_7_2","volume-title":"Immunobiology: The Immune System in Health and Disease","author":"Janeway CA"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genet.39.073003.110544"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.275"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(02)00409-0"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0019-2805.2001.01341.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009483200"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.346"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508123103"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1128\/cdli.1.4.365-372.1994","article-title":"Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?","volume":"1","author":"Kuus\u2010Reichel K","year":"1994","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/13.12.1551"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1837"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.21.6851"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/312643a0"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.6.342"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5699(00)01680-7"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/321522a0"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10029"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2005.01.002"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1126"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1135"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20178"},{"key":"e_1_2_7_28_2","first-page":"172","article-title":"Immunogenicity of therapeutic monoclonal antibodies","volume":"5","author":"Pendley C","year":"2003","journal-title":"Curr Opin Mol Ther."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.10346"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20125"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90087-4"},{"key":"e_1_2_7_32_2","volume-title":"Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","author":"Food and Drug Administration","year":"2005"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.10531"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-005-6196-y"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068087"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra055446"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.311.5768.1688"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.313.5789.901a"},{"key":"e_1_2_7_39_2","volume-title":"Guidance for Industry: E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs","author":"Food and Drug Administration","year":"2005"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.2174\/138920006774832604"},{"key":"e_1_2_7_41_2","unstructured":"National Institutes of Health Clinical Trials.www.clinicaltrials.gov."},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.7182\/prtr.1.6.3.8145l3u185493182"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C039"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04045.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1110"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04044.x"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410017284"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2005.02191.x"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G074"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1752"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19126"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.17.1680"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.76"},{"key":"e_1_2_7_54_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1681\/ASN.V52177","article-title":"Reduced production, absorption and elimination of erythropoietin in uremia compared with healthy volunteers","volume":"5","author":"Jensen JD","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_7_55_2","first-page":"847","article-title":"A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis","volume":"33","author":"Westhovens R","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X120931"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1130"},{"key":"e_1_2_7_58_2","first-page":"11","article-title":"Biomarkers: strategies to predict outcome of rheumatoid arthritis","volume":"3","author":"Saleem B","year":"2006","journal-title":"Drug Discovery Today"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.7.4917"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23448.x"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90628-9"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270006298360","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270006298360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T20:11:17Z","timestamp":1697141477000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270006298360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1177\/0091270006298360"],"URL":"https:\/\/doi.org\/10.1177\/0091270006298360","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}